{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:15Z","timestamp":1786116735848,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK13593701A1"],"award-info":[{"award-number":["R01DK13593701A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10620-026-09753-5","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:31:55Z","timestamp":1771270315000},"page":"2966-2975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials"],"prefix":"10.1007","volume":"71","author":[{"given":"Dhruv","family":"Ahuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyoun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane W.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"9753_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/ecco-jcc\/jjac177","volume":"17","author":"K Kontola","year":"2023","unstructured":"Kontola K, Oksanen P, Huhtala H, Jussila A. Increasing Incidence of Inflammatory Bowel Disease, with Greatest Change Among the Elderly: A Nationwide Study in Finland, 2000\u20132020. J Crohns Colitis. 2023;17:706\u2013711.","journal-title":"J Crohns Colitis."},{"key":"9753_CR2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2022.07.062","volume":"163","author":"M Agrawal","year":"2022","unstructured":"Agrawal M, Christensen HS, B\u00f8gsted M, Colombel JF, Jess T, Allin KH. The Rising Burden of Inflammatory Bowel Disease in Denmark Over Two Decades: A Nationwide Cohort Study. Gastroenterology. 2022;163:1547\u201354.e5.","journal-title":"Gastroenterology."},{"key":"9753_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2468-1253(22)00358-2","volume":"8","author":"S Singh","year":"2023","unstructured":"Singh S, Boland BS, Jess T, Moore AA. Management of inflammatory bowel diseases in older adults. Lancet Gastroenterol Hepatol. 2023;8:368\u2013382.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"9753_CR4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.cgh.2024.08.011","volume":"23","author":"S Singh","year":"2024","unstructured":"Singh S, Poulsen GJ, Bisgaard TH, Bonfils L, Jess T. Epidemiology of Elderly Onset IBD: A Nationwide Population-Based Cohort Study. Clin Gastroenterol Hepatol. 2024;23:1204.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9753_CR5","doi-asserted-by":"crossref","unstructured":"Xu F CS, Liu Y, Greenlund KJ. Prevalence of Inflammatory Bowel Disease Among Medicare Fee-For-Service Beneficiaries \u2014 United States, 2001\u22122018. MMWR Morb Mortal Wkly Rep; 2021.","DOI":"10.15585\/mmwr.mm7019a2"},{"key":"9753_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MIB.0000000000001099","volume":"23","author":"AN Ananthakrishnan","year":"2017","unstructured":"Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882\u2013893.","journal-title":"Inflamm Bowel Dis."},{"key":"9753_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","volume":"156","author":"S Coward","year":"2019","unstructured":"Coward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345\u201353.e4.","journal-title":"Gastroenterology."},{"key":"9753_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12876-020-01296-x","volume":"20","author":"I Zammarchi","year":"2020","unstructured":"Zammarchi I, Lanzarotto F, Cannatelli R, Munari F, Benini F, Pozzi A et al. Elderly-onset vs adult-onset ulcerative colitis: a different natural history? BMC Gastroenterol. 2020;20:147.","journal-title":"BMC Gastroenterol."},{"key":"9753_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000522569","volume":"69","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lv H, Yang H, Zhang H, Bai X, Qian J. Elderly Patients with Moderate-To-Severe Ulcerative Colitis Are More Likely to Have Treatment Failure and Adverse Outcome. Gerontology. 2023;69:119\u2013129.","journal-title":"Gerontology."},{"key":"9753_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2017.10.034","volume":"154","author":"\u00c5H Everhov","year":"2018","unstructured":"Everhov \u00c5H, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, S\u00f6derling J et al. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology. 2018;154:518\u201328.e15.","journal-title":"Gastroenterology."},{"key":"9753_CR11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cgh.2020.02.048","volume":"18","author":"JJ Rozich","year":"2020","unstructured":"Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol. 2020;18:2437\u201347.e6.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"9753_CR12","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/ecco-jcc\/jjaa012","volume":"14","author":"ME de Jong","year":"2020","unstructured":"de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel M, R\u00f6mkens TEH et al. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients. J Crohns Colitis. 2020;14:888\u2013895.","journal-title":"J Crohns Colitis."},{"key":"9753_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cgh.2020.04.070","volume":"19","author":"D Cheng","year":"2021","unstructured":"Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and efficacy of tumor necrosis factor antagonists in older patients with ulcerative colitis: patient-level pooled analysis of data from randomized trials. Clinical Gastroenterology and Hepatology. 2021;19:939\u201346.e4.","journal-title":"Clinical Gastroenterology and Hepatology."},{"key":"9753_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","volume":"34","author":"V Yajnik","year":"2017","unstructured":"Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B et al. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn\u2019s Disease Patients Stratified by Age. Adv Ther. 2017;34:542\u2013559.","journal-title":"Adv Ther."},{"key":"9753_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/jcm13020365","volume":"13","author":"T Holvoet","year":"2024","unstructured":"Holvoet T, Truyens M, De Galan C, Peeters H, Gismero FM, Elorza A et al. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. J Clin Med. 2024;13:365.","journal-title":"J Clin Med."},{"key":"9753_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","volume":"29","author":"GR Lichtenstein","year":"2023","unstructured":"Lichtenstein GR, Bressler B, Francisconi C, Vermeire S, Lawendy N, Salese L et al. Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis. 2023;29:27\u201341.","journal-title":"Inflamm Bowel Dis."},{"key":"9753_CR17","doi-asserted-by":"crossref","unstructured":"A Historic Moment for Open Science: The Yale University Open Data Access Project and Medtronic. 107326\/0003-4819-158-12-201306180-00009. 2013.","DOI":"10.7326\/0003-4819-158-12-201306180-00009"},{"key":"9753_CR18","unstructured":"Vivli - Center for Global Clinical Research Data 2025 [Available from: https:\/\/vivli.org\/."},{"key":"9753_CR19","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462\u20132476.","journal-title":"N Engl J Med."},{"key":"9753_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, D\u2019Haens G, Hanauer S, Schreiber S et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780\u2013787.","journal-title":"Gut."},{"key":"9753_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D\u2019Haens G, Wolf DC et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65e1-3.","journal-title":"Gastroenterology."},{"key":"9753_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","volume":"146","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85\u201395.","journal-title":"Gastroenterology."},{"key":"9753_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med."},{"key":"9753_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, O\u2019Brien CD, Zhang H, Johanns J et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381:1201\u20131214.","journal-title":"N Engl J Med."},{"key":"9753_CR25","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med."},{"key":"9753_CR26","unstructured":"CFR - Code of Federal Regulations Title 21. 2025."},{"key":"9753_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"2012","unstructured":"Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Safety. 2012;20:109\u2013117.","journal-title":"Drug Safety."},{"key":"9753_CR28","unstructured":"Use ICfHoTRfPfH. ICH Harmonised Tripartite Guideline E2A: Clinical Safety Data Management\u2014Definitions and Standards for Expedited Reporting. 1994."},{"key":"9753_CR29","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702\u2013706.","journal-title":"Am J Epidemiol."},{"key":"9753_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0962280211427759","volume":"22","author":"GY Zou","year":"2013","unstructured":"Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013;22:661\u2013670.","journal-title":"Stat Methods Med Res."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09753-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09753-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:54:10Z","timestamp":1786017250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09753-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["9753"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09753-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JC: No relevant disclosures. DA: No relevant disclosures. GZ: Consultancy\/advisory board fees from Alimentiv Inc. SWG: No relevant disclosures. VJ: Consultancy\/advisory board fees from AbbVie, Alimentiv Inc., Arena pharmaceuticals, Asahi Kasei Pharma, Asieris, Astra Zeneca, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Flagship Pioneering, Fresenius Kabi, Galapagos, GlaxoSmithKline, Genentech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Protagonist, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx, and Vividion; and speaker\u2019s fees from, Abbvie, Ferring, Galapagos, Janssen Pfizer Shire, Takeda, and Fresenius Kabi. SS: has received research grants from Pfizer.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This publication (Vivli protocol #00006551) is based on research using data from AbbVie, Takeda and Pfizer that have been made available through Vivli. Vivli has not contributed to or approved, and is not in any way responsible for, the contents of this publication. Part of this study, carried out under YODA Project #2022\u20134975 used data obtained from the Yale University Open Data Access Project, which has an agreement with JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. The interpretation and reporting of research using this data are solely the responsibility of the authors and does not necessarily represent the official views of the Yale University Open Data Access Project or JANSSEN RESEARCH & DEVELOPMENT, L.L.C.. The original proposal can be found:\u00a0\n                      \n                      .","order":2,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Local research ethics review was not required because the data were already previously collected and deidentified, and no informed consent was required.","order":3,"name":"Ethics","label":"Ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}